Neutralizing antibodies take a swipe at HIV in vivo

Abstract

Developing an effective AIDS vaccine may hinge on understanding how to elicit antibodies that recognize and disable the HIV virus-but first, experiments in people must show that such antibodies are even useful in controlling infection. Information from a recent human trial provides hope that controlling the virus by neutralizing antibodies might be possible. And another study examines why the antibodies are so difficult to elicit.